معرفی
Emma Allen-Vercoe is a Professor and Canada Research Chair in Human Gut Microbiome Function and Host Professor at the University of Guelph's Department of Molecular and Cellular Biology, College of Biological Science. Her research focuses on the human gut microbiota's role in health and disease, particularly in colorectal cancer, diabetes, and inflammatory bowel diseases. She co-founded NuBiyota, a company developing microbial ecosystem therapeutics. Key innovations include the Robogut bioreactor system for studying gut microbiota dynamics. She has advised numerous graduate students and holds grants from agencies like CIHR, NIH, and NSERC. Her work spans human and honey bee microbiome research, emphasizing translational applications.
Education: B.Sc. (Hons) Biochemistry from University of London; Ph.D. Molecular Biology from Open University/CAMR, UK; Postdoc at University of Calgary.
Research Interests: Anaerobic bacteriology, gut microbial dysbiosis, microbiome-driven diseases, and probiotic development. Notable projects include studying Fusobacterium nucleatum in colorectal cancer and Yanomami gut microbiome preservation.
Grants & Awards: Canada Research Chair, Fellow-to-Faculty Transition Award (Canadian Association of Gastroenterology), and collaborations with institutions like SickKids and the Broad Institute.
Labs/Teams: Leads the Allen-Vercoe Lab at University of Guelph, pioneering the Canadian Bee Gut Project and culturomics initiatives through the MiPAC facility.
